Blend Blend · one vial
CJC-1295 / Ipamorelin
GHRH + GHRP blend (no DAC)
Common 1:1 blend pairing a GHRH analog with a selective GH secretagogue for pulsatile GH release research.
What's in it
2 ingredients pre-mixed in one vial. Tap one to open its own page.
5 mg CJC-1295 (no DAC) · 5 mg Ipamorelin
Per vial · verified against reference guide
- 015 mg / vial
CJC-1295 (no DAC)
Not yet in catalog — no separate page for this ingredient.
- 025 mg / vial
Ipamorelin
Selective ghrelin-receptor agonist (GHRP) researched for GH release with minimal cortisol/prolactin effect.
How it works: Ipamorelin is a synthetic pentapeptide that releases growth hormone through the ghrelin (GH secretagogue) receptor, like GHRP-6.
Open Ipamorelin →
Schedule on file
Research reference from the compound page, not instructions for human use.
Protocol card · research reference
- Starting dose
- 0.1 mg each
- Studied range
- 0.1–0.3 mg each
- Frequency
- Once daily, before bed, 5 days on / 2 off
- Route
- Subcutaneous
- Cycle
- 8–12 weeks
Reconstitution reference
Storage: Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
CJC-1295 / Ipamorelin
Once daily, before bed, 5 days on / 2 off · units to draw on a U-100 syringe for a 0.2 mg dose.
| Vial | BAC water | mg/mL | Draw | Doses |
|---|---|---|---|---|
| 10 mg | 1 mL | 10 | 2 u | 50 |
| 10 mg | 2 mL | 5 | 4 u | 50 |
| 10 mg | 3 mL | 3.33 | 6 u | 50 |
Notes
- Fasted administration is typical in research protocols.